HB-2121

HB-2121 is an orally administered diagnostic agent being developed for the detection and monitoring of celiac disease. It functions by binding to active transglutaminase 2 (TG2) in the small intestine, an enzyme that becomes highly active in individuals with celiac disease, particularly upon gluten exposure. By marking active TG2, HB-2121 allows for the detection and quantification of enzyme activity during diagnostic procedures such as esophagogastroduodenoscopy (EGD). This tool is intended to assist in diagnosis and disease monitoring even in the absence of gluten consumption. It is currently being evaluated in Phase 1 clinical trials led by researchers at Stanford University, including Dr. Nielsen Fernandez-Becker.